This trial is active, not recruiting.

Condition acute coronary syndrome
Sponsor Chattanooga-Hamilton County Hospital Authority
Start date January 2014
End date December 2014
Trial size 1000 participants
Trial identifier NCT02002546, IRB# 13-069


1. In chest pain patients with suspected acute coronary syndrome, a 2-hr delta Troponin-I as measured by the i-STAT immunoassay reliably identifies and excludes an acute myocardial infarction.

2. In chest pain patients with suspected acute coronary syndrome whose baseline troponin is above the 99th percentile but less than 0.2ng/ml, a 2hr delta Troponin-I as measured by the i-STAT immunoassay accurately discriminates between acute myocardial infarction and non-acute myocardial infarction troponin elevations.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective

Primary Outcomes

Change in Troponin value over a two hour interval.
time frame: 2 hours after baseline

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Adult patients 18 years of age or older 2. Chest pain suspicious for ACS 3. Absence of ST-segment elevation AMI (STEMI) or STEMI equivalent on the initial ECG 4. Baseline i-STAT troponin less or equal to 1.0 ng/ml 5. Enrollment initiated before 2 hour 'delt' troponin value available for review 6. Ability and willingness to participate and cooperate with telephone follow-up evaluations Exclusion Criteria: 1. ST-elevation or other ECG criteria that results in the diagnosis of AMI and results in patient being sent for percutaneous coronary interventions (PCI) or being treated with thrombolytics 2. Patients with chest pain not deemed to warrant cardiac screening 3. Blunt chest trauma 4. Tachyarrhythmia (ventricular tachycardia, supraventricular tachycardia, or rapid atrial fibrillation) 5. Cardiac Arrest prior to arrival 6. Hemodynamically unstable patients 7. Pulmonary edema requiring CPAP, BIPAP, or mechanical ventilation 8. Baseline i-STAT troponin measurement greater than 1.0 ng/ml 9. Baseline and 2-hour i-STAT Troponin measurements not obtained 10. Patient (or Legal Representative) unable or unwilling to provide written informed consent 11. Subject unwilling or unlikely to comply with study procedures, including protocol-specific blood sampling 12. Subject unwilling, unable, or deemed unlikely to respond or participate in telephone follow-up 13. Vulnerable populations as deemed inappropriate for the study

Additional Information

Official title Usefulness of a 2-hour Delta Troponin-I During the ED Identification and Exclusion of Acute Myocardial Infarction
Description Primary Aims: 1) Demonstrate that a 2hr delta troponin as measured by the i-STAT platform can reliably identify and exclude MI on the initial ED evaluation. 2)Demonstrate that a 2hr delta troponin is useful in the discrimination AMI versus non-AMI conditions in patients with low abnormal baseline Troponin-I values. Secondary Aims: 1) Demonstrate that a positive 2-hr delta troponin-I identifies patients at highest risk for 30 day ACE. 2) Other Secondary aims TBD.
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by Chattanooga-Hamilton County Hospital Authority.